EKF Diagnostics Holdings PLC Update regarding AIM admission of RenalytixAI (1097G)
November 01 2018 - 12:30PM
UK Regulatory
TIDMEKF TIDMTTM
RNS Number : 1097G
EKF Diagnostics Holdings PLC
01 November 2018
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Update regarding AIM admission of RenalytixAI and planned change
of EKF's nominated adviser
EKF Diagnostics Holdings plc (AIM: EKF) announces that, further
to the announcement on 31 October confirming that Renalytix AI plc
("RenalytixAI") had successfully raised GBP22.25 million in gross
proceeds, RenalytixAI will now be admitted to trading on AIM on 6
November 2018. An updated Schedule One announcement is expected to
be issued on 2 November 2018.
Participants in the fundraising will be contacted by N+1 Singer,
the Company or Link Asset Services to confirm updated settlement
instructions.
EKF and N+1 Singer, the Company's current nominated adviser and
broker, have agreed that in order to preserve the independence of
its nominated adviser, EKF will appoint a new nominated adviser
after the admission of RenalytixAI. A further announcement will be
made in this regard in due course.
N+1 Singer will continue to act as broker to EKF.
Enquiries:
EKF Diagnostics Holdings plc
Christopher Mills, Non-Executive Chairman Tel: 029 2071 0570
Julian Baines, CEO
Richard Evans, FD & COO
N+1 Singer (Nominated Adviser & Broker) Tel: 020 7496 3000
Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: 020 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303
About EKF Diagnostics Holdings plc www.ekfdiagnostics.com
EKF is a leading point-of-care diagnostics and central
laboratory assay manufacturer with an estimated 80,000 hemoglobin,
hematocrit, HbA1c, glucose and lactate analyzers in regular use
across more than 100 countries. EKF specializes in developing tests
for use in anemia and diabetes diagnosis and management, as well as
providing a portfolio of reagents for use in clinical chemistry
analyzers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDDFLFBVFFLFBD
(END) Dow Jones Newswires
November 01, 2018 13:30 ET (17:30 GMT)
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Apr 2024 to May 2024
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From May 2023 to May 2024